“Bevacizumab (Bev) with irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) i.v. every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): an observational study of the Southern Italy Cooperative Oncology Group (SICOG)”

Sergio Palmeri

“Bevacizumab (Bev) with irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) i.v. every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): an observational study of the Southern Italy Cooperative Oncology Group (SICOG)”

Discipline Chirurgiche, Oncologiche e Stomatologiche

Risultato della ricerca: Other

Lingua originale	English
Numero di pagine	1
Stato di pubblicazione	Published - 2009

Altri file e collegamenti

OA Link

Cita questo

@conference{1888c268fedb4e13844f90cc31cb7544,

title = "“Bevacizumab (Bev) with irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) i.v. every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): an observational study of the Southern Italy Cooperative Oncology Group (SICOG)”",

keywords = "bevacizumab, metastatic colorectal cancer, bevacizumab, metastatic colorectal cancer",

author = "Sergio Palmeri",

year = "2009",

language = "English",

}

TY - CONF

T1 - “Bevacizumab (Bev) with irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) i.v. every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): an observational study of the Southern Italy Cooperative Oncology Group (SICOG)”

AU - Palmeri, Sergio

PY - 2009

Y1 - 2009

KW - bevacizumab

KW - metastatic colorectal cancer

KW - bevacizumab

KW - metastatic colorectal cancer

UR - http://hdl.handle.net/10447/45336

M3 - Other

ER -